文献速递血液透析通路

辅助性血管内介入促进动静脉瘘成熟的结局分析

Arteriovenous fistula formation with adjuvant endovascular maturation.
PubMed 文献 · J Vasc Surg · 2021-09-08

该回顾性研究纳入82例终末期肾衰患者,评估早期选择性血管内介入对动静脉瘘(AVF)成熟的影响。结果显示,93.9%的AVF在6个月内达到功能性成熟,平均成熟时间67.8±65.9天;成熟后初级通畅率6个月为82%±4.3%,48个月为34%±6.8%;辅助初级通畅率48个月为83%±4.7%;血管内再干预率为0.37次/患者年。结论认为早期选择性介入可提高AVF成熟率并缩短成熟时间。

要点

  • 早期选择性血管内介入可使93.9%的AVF在6个月内达到功能性成熟。
  • 成熟后辅助初级通畅率48个月达83%±4.7%,再干预率0.37次/患者年。
  • 所有血栓形成均可通过血管内技术挽救,4年二次功能性通畅率100%。

核心结论

  • 早期选择性血管内介入可提高AVF成熟率并缩短成熟时间,实现近乎普遍的成熟。
  • 成熟后持续血管内再干预可维持低再干预率和长期通畅,提供可靠的长期肾血管通路。

研究设计与样本

  • 单中心回顾性研究,纳入2014年2月至2020年2月期间82例 consecutive 终末期肾衰患者(平均年龄62.5±13.5岁,范围17-83;58例男性,占70.7%),均接受血管通路构建。
  • 分析4年AVF通畅率、血管直径、血液透析参数、再干预率和死亡率。

主要发现

  • 桡头AVF最常见(71例,88.6%)。
  • AVF形成后平均46.2±56.0天(范围5-343天)评估发现33例(40.2%)未成熟。
  • 19例患者接受血管内介入(包括吻合口附近、穿刺区和/或流出道的血管成形术和/或支架植入)以促进及时成熟。
  • 93.9%的AVF在形成后6个月内达到功能性通畅(成熟),平均成熟时间67.8±65.9天(范围5-320天)。
  • 成熟后初级通路功能性通畅率:6个月82%±4.3%,12个月58%±5.5%,48个月34%±6.8%。

临床怎么用

  • 对于AVF形成后早期评估未成熟的病例,可选择性采用血管内介入(血管成形术和/或支架植入)促进成熟。
  • 成熟后维持定期监测,必要时行血管内再干预以维持长期通畅。

局限性

  • 回顾性单中心研究,样本量82例,可能存在选择偏倚。
  • 未设置对照组,无法直接比较早期介入与保守治疗的差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical utility of the native arteriovenous fistula (AVF) has been limited by the prolonged time required for maturation, the low overall maturation rate, and subsequent abandonment. Endovascular intervention has been increasingly accepted as the first-line therapy for AVF stenosis. The objective of the present study was to evaluate the AVF formation outcomes when early endovascular intervention was selectively performed to bring about timely AVF maturation. METHODS: We performed a retrospective study (February 2014 to February 2020) of 82 AVF consecutive patients (mean age, 62.5 ± 13.5 years; range, 17-83; 58 men [70.7%]) with end-stage renal failure who had undergone vascular access construction at a single institution. The 4-year AVF patency, vascular diameters, hemodialysis parameters, reintervention rate, and mortality were analyzed. RESULTS: Radiocephalic AVF was the most common fistula constructed (71 patients; 88.6%). The evaluation at a mean of 46.2 ± 56.0 days (range, 5-343 days) after AVF formation revealed 33 immature AVFs (40.2%). Subsequently, 19 patients had undergone endovascular procedures, including angioplasty and/or stenting of the juxta-anastomosis, cannulation zones, and/or outflow segments to bring about timely maturation of the AVF. Hence, 93.9% of the AVFs had reached functional patency (maturation) by 6 months after formation, with a mean time to maturation of 67.8 ± 65.9 days (range, 5-320 days). After reaching maturation, the primary access functional patency was 82% ± 4.3% at 6 months, 58% ± 5.5% at 12 months, and 34% ± 6.8% at 48 months. The primary assisted access functional patency was 95% ± 2.4% at 6 months, 90% ± 3.3% at 12 months, and 83% ± 4.7% at 48 months. A total of 121 endovascular interventions were performed to maintain patency, equating to an endovascular reintervention rate of 0.37 procedure/patient year. The mean arterial, venous, and brachial flow rates did not change significantly after maturation with a mean AVF (primary assisted functional patency) survival time of 5.9 ± 0.26 years (range, 5.33-6.36 years) from maturation. Only 12 thromboses had occurred after the first follow-up review after AVF formation. These were all salvaged using endovascular techniques, leading to 100% total secondary functional patency at 4 years. The 5-year estimated all-cause mortality was 45.6% ± 12.7%. CONCLUSIONS: The AVF maturation rate and interval to maturation were improved when early endovascular intervention was selectively performed after AVF formation. This allowed for near universal maturation. In addition, once matured, the use of ongoing endovascular reinterventions allowed for a low reintervention rate and long-term patency, providing reliable long-term renal vascular access.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Thomas SD, Sideris A, Narroway H, et al. Arteriovenous fistula formation with adjuvant endovascular maturation. J Vasc Surg. 2021. PMID: 34506894. doi:10.1016/j.jvs.2021.08.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。